AxoGen

Peripheral nerve damage is estimated to affect more than 20 million people in the United States, causing symptoms that range from mild discomfort to severe disability. Damage is often undiagnosed or untreated, and the current standard of care procedures can be associated with limitations that impact the quality of life. UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair, aims to address these issues and provide more efficient treatment options to patients.